September 2022, Vol 140, No. 9, Pages 843-912
Original Investigation
1. Predicted vs Observed Metastasis-Free Survival in Individuals With Uveal Melanoma
- Arun D. Singh, MD; Elaine M. Binkley, MD; Jacquelyn M. Wrenn, CNP; et al.
- JAMA Ophthalmol. 2022;140(9):847-854. doi:10.1001/jamaophthalmol.2022.2623
- PDF
2. Association Between Open Payments–Reported Industry Transfers of Value and Prostaglandin Analog Prescribing in the US
- Andrew M. Nguyen, BS, BA; Kelly E. Anderson, PhD, MPP; Gerard Anderson, PhD; et al.
- JAMA Ophthalmol. 2022;140(9):855-862. doi:10.1001/jamaophthalmol.2022.2757
- PDF
3. Association Between Myopic Refractive Error and Primary Open-Angle GlaucomaA 2-Sample Mendelian Randomization Study
- Hélène Choquet, PhD; Anthony P. Khawaja, PhD; Chen Jiang, PhD; et al.
- JAMA Ophthalmol. 2022;140(9):864-871. doi:10.1001/jamaophthalmol.2022.2762
- PDF
4. Effect of Modified Vertical Rectus Belly Transposition vs Augmented Superior Rectus Transposition Plus Medial Rectus Recession for Chronic Sixth Nerve PalsyA Randomized Clinical Trial
- Jing Yao, MD; Chao Jiang, MD; Xiying Wang, MD; et al.
- JAMA Ophthalmol. 2022;140(9):872-879. doi:10.1001/jamaophthalmol.2022.2856
- PDF
5. Risk of Ocular Adverse Events With Taxane-Based Chemotherapy
- Mohit Sodhi, MSc; Sonia N. Yeung, MD, PhD; David Maberley, MD, MSc; et al.
- JAMA Ophthalmol. 2022;140(9):880-884. doi:10.1001/jamaophthalmol.2022.3026
- PDF
Brief Report
6. Characteristics of Semiautomated Endothelial Cell–Density Measurements Among Corneal Donor Eyes
- Wuqaas M. Munir, MD; Saleha Z. Munir, OD
- JAMA Ophthalmol. 2022;140(9):885-888. doi:10.1001/jamaophthalmol.2022.2782
- PDF
7. Severe Familial Exudative Vitreoretinopathy, Congenital Hearing Loss, and Developmental Delay in a Child With Biallelic Variants in FZD4
- Sarah R. van der Ende, BSc; Benjamin S. Meyers, MD; Jenina E. Capasso, MS, LCGC; et al.
- JAMA Ophthalmol. 2022;140(9):889-893. doi:10.1001/jamaophthalmol.2022.2914
- PDF
8. COVID-19 Vaccination Rates Among US Adults With Vision or Hearing Disabilities
- Kea Turner, PhD, MPH, MA; Oliver T. Nguyen, MSHI; Amir Alishahi Tabriz, MD, PhD, MPH; et al.
- JAMA Ophthalmol. 2022;140(9):894-899. doi:10.1001/jamaophthalmol.2022.3041
- PDF
Invited Commentary
9. Small Payments, Large Consequences
- Roni M. Shtein, MD, MS; Paul R. Lichter, MD, MS; Paul P. Lee, MD, JD
- JAMA Ophthalmol. 2022;140(9):862-863. doi:10.1001/jamaophthalmol.2022.2763
- PDF
New Instrument
10. A Modified Trocar and Cannula System With Lateral Micropores for 1-Step Drainage of Suprachoroidal Fluid During Primary Vitrectomy
- Wen-wen Zhang, MD, MS; Feng Jiang, MD, PhD; Zheng-gao Xie, MD, PhD
- JAMA Ophthalmol. 2022;140(9):900-901. doi:10.1001/jamaophthalmol.2022.2597
- PDF
JAMA Ophthalmology Clinical Challenge
11. Middle-aged Woman With Atypical Upper Eyelid Retraction
- Natalie A. Homer, MD; Morgan Darrow, MD
- JAMA Ophthalmol. 2022;140(9):902-903. doi:10.1001/jamaophthalmol.2022.1532
- PDF
12. Pigmented Corneal Mass in a 59-Year-Old Man With Cutaneous Melanoma
- Nita G. Valikodath, MD, MS; Abdulrahman Rageh, MD; Miguel A. Materin, MD
- JAMA Ophthalmol. 2022;140(9):904-905. doi:10.1001/jamaophthalmol.2022.1537
- PDF
13. Persistent Vascular Lesion in a Young Boy
- Tonya Lee, BS; Mansoor Movaghar, MD; Catherine Y. Liu, MD, PhD
- JAMA Ophthalmol. 2022;140(9):906-907. doi:10.1001/jamaophthalmol.2022.1541
- PDF
Ophthalmic Images
14. Numerous Peripheral Retinal Yellow Flecks in an Adult Woman
- Maamouri Rym, MD; Beizig Olfa, MD; Cheour Monia, MD
- JAMA Ophthalmol. 2022;140(9):e222764. doi:10.1001/jamaophthalmol.2022.2764
- PDF
15. Unilateral Intracorneal Primary Pigmented Iris Cyst in a Man Aged 34 Years
- Arnav Panigrahi, MBBS; Shikha Gupta, MD; Noopur Gupta, MS, PhD
- JAMA Ophthalmol. 2022;140(9):e222880. doi:10.1001/jamaophthalmol.2022.2880
- PDF
16. Corneal Wound Associated With Orthokeratology Lenses
- Chang Liu, MD, PhD; Yao Ni, MD, PhD
- JAMA Ophthalmol. 2022;140(9):e223044. doi:10.1001/jamaophthalmol.2022.3044
- PDF
17. Chemotherapy-Induced Hyperopic Surprise in a Woman With Multiple Myeloma
- Anh D. Bui, MD, PhD; Sarah Lopez, OD; Gerami D. Seitzman, MD
- JAMA Ophthalmol. 2022;140(9):e223226. doi:10.1001/jamaophthalmol.2022.3226
- PDF
Comment & Response
18. In Defense of Phosphodiesterase 5 Inhibitors
- Federico Belladelli, MD; Francesco Del Giudice, MD; Michael L. Eisenberg, MD
- JAMA Ophthalmol. 2022;140(9):908. doi:10.1001/jamaophthalmol.2022.2612
- PDF
19. In Defense of Phosphodiesterase 5 Inhibitors—Reply
- Mohit Sodhi, MSc, MD; Frederick S. Mikelberg, MD; Mahyar Etminan, PharmD, MSc
- JAMA Ophthalmol. 2022;140(9):908-909. doi:10.1001/jamaophthalmol.2022.2615
- PDF
20. Questions Regarding the 2019 Quality Payment Program Performance for Ophthalmologists
- Flora Lum, MD; David Glasser, MD; Cathy G. Cohen, MHSA
- JAMA Ophthalmol. 2022;140(9):909. doi:10.1001/jamaophthalmol.2022.2804
- PDF
21. Questions Regarding the 2019 Quality Payment Program Performance for Ophthalmologists—Reply
- Sean T. Berkowitz, MD, MBA; Shriji Patel, MD, MBA
- JAMA Ophthalmol. 2022;140(9):909-910. doi:10.1001/jamaophthalmol.2022.2807
- PDF
22. Plasma Levels of Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity Study—More Questions Than Answers
- Talkad S. Raghuveer, MD; Stephanie Binder, MD
- JAMA Ophthalmol. 2022;140(9):910-911. doi:10.1001/jamaophthalmol.2022.2884
- PDF
23. Plasma Levels of Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity Study—More Questions Than Answers?—Reply
- M. Elizabeth Hartnett, MD; David K. Wallace, MD, MPH
- JAMA Ophthalmol. 2022;140(9):911-912. doi:10.1001/jamaophthalmol.2022.2887
- PDF
Correction
24. Error in Number of Participants Reported
- JAMA Ophthalmol. 2022;140(9):912. doi:10.1001/jamaophthalmol.2022.2891
- PDF
25. Correction to Data Points in Figure
- JAMA Ophthalmol. 2022;140(9):912. doi:10.1001/jamaophthalmol.2022.3302
- PDF
JAMA Ophthalmology Masthead
26. JAMA Ophthalmology
- JAMA Ophthalmol. 2022;140(9):843. doi:10.1001/jamaophthalmol.2021.4263
- PDF